Nanobiotix Announces New Organizational Structure as the Company Enters its Next Stage After First European Market Approval

Paris, France and Cambridge, Massachusetts, USA, Jul. 1 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced organizational  changes to align with strategic priorities post European market approval for Hensify® (NBTXR3). The changes aim to reinforce necessary competencies as strategic priorities [...]